Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

GMED or PEN: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Dec 3, 2025

Here's Why Penumbra (PEN) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Nov 27, 2025

Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.

PRNewsWire • Nov 19, 2025

Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 18, 2025

Penumbra Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand

PEN's Q3 results impress with double-digit sales growth, margin expansion and a strong 20% stock surge after its earnings beat.

Zacks Investment Research • Nov 11, 2025

Why Penumbra (PEN) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Nov 10, 2025

Penumbra Shoots For A Breakout On 'Another Impressive Quarter'

Penumbra stock skyrocketed Thursday after the medtech company beat third-quarter expectations on the back of its blood-clot-removing tech.

Investors Business Daily • Nov 6, 2025

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

Penumbra, Inc. ( PEN ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Cecilia Furlong Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Maggie Yuen - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Vijay Kumar - Evercore Inc. Brandon Vazquez - William Blair & Company L.L.C., Research Division William Plovanic - Canaccord Genuity Corp., Research Division Michael Sarcone - Jefferies LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Presentation Operator Ladies and gentlemen, good afternoon.

Seeking Alpha • Nov 6, 2025

Penumbra, Inc. Reports Third Quarter 2025 Financial Results

ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.

PRNewsWire • Nov 5, 2025